Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,886,592
  • Shares Outstanding, K 3,099,600
  • Annual Sales, $ 37,417 M
  • Annual Income, $ 112,000 K
  • 60-Month Beta 0.51
  • Price/Sales 4.44
  • Price/Cash Flow 13.97
  • Price/Book 5.59
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 26.22% ( -0.03%)
  • Historical Volatility 18.06%
  • IV Percentile 42%
  • IV Rank 28.67%
  • IV High 38.30% on 10/11/22
  • IV Low 21.36% on 12/02/22
  • Put/Call Vol Ratio 2.51
  • Today's Volume 3,630
  • Volume Avg (30-Day) 7,293
  • Put/Call OI Ratio 1.23
  • Today's Open Interest 115,134
  • Open Int (30-Day) 138,234

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.71
  • Number of Estimates 5
  • High Estimate 0.85
  • Low Estimate 0.63
  • Prior Year 0.84
  • Growth Rate Est. (year over year) -15.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.51 +2.84%
on 02/02/23
72.12 -10.86%
on 01/10/23
-6.51 (-9.19%)
since 01/06/23
3-Month
60.96 +5.46%
on 11/09/22
72.12 -10.86%
on 01/10/23
+3.19 (+5.22%)
since 11/07/22
52-Week
52.65 +22.11%
on 09/26/22
72.12 -10.86%
on 01/10/23
+7.61 (+13.43%)
since 02/07/22

Most Recent Stories

More News
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

AZN : 64.29 (+1.21%)
MRK : 105.68 (+1.59%)
ALKS : 27.18 (+0.30%)
BAYRY : 15.9200 (+1.66%)
BiondVax (NASDAQ: BVXV) Aiming to Capture Market Share for Treatment, Prevention of COVID-19

The Food and Drug Administration (“FDA”) recently withdrew the authorization of AstraZeneca PLC (NASDAQ: AZN) ’s Evusheld, a combination of two monoclonal antibodies (“mAbs”), which was being...

BVXV : 2.59 (-7.17%)
PFE : 43.59 (-0.39%)
AZN : 64.29 (+1.21%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

PFE : 43.59 (-0.39%)
DSNKY : 31.0240 (+0.66%)
GILD : 86.05 (-0.36%)
AZN : 64.29 (+1.21%)
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.

AZN : 64.29 (+1.21%)
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

AZN : 64.29 (+1.21%)
GSK : 36.17 (+2.35%)
AKBA : 1.1300 (+5.61%)
FGEN : 25.18 (+1.00%)
3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally...

AZN : 64.29 (+1.21%)
BMY : 74.52 (-0.01%)
GSK : 36.17 (+2.35%)
Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.

SNY : 46.97 (+2.42%)
AZN : 64.29 (+1.21%)
NVO : 139.59 (+1.10%)
MRK : 105.68 (+1.59%)
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

AstraZeneca and Amgen’s TEZSPIRE ® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE...

AZN : 64.29 (+1.21%)
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints

Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.

AZN : 64.29 (+1.21%)
AMGN : 244.00 (+0.06%)
HZNP : 109.80 (-0.41%)
ABBV : 145.14 (+0.08%)
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023

These healthcare titans are poised for a strong showing in 2023 and beyond.

AZN : 64.29 (+1.21%)
MRK : 105.68 (+1.59%)
MDT : 86.58 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 65.93
2nd Resistance Point 65.16
1st Resistance Point 64.73
Last Price 64.29
1st Support Level 63.52
2nd Support Level 62.75
3rd Support Level 62.32

See More

52-Week High 72.12
Fibonacci 61.8% 64.68
Last Price 64.29
Fibonacci 50% 62.39
Fibonacci 38.2% 60.09
52-Week Low 52.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar